Determining medical decision-making capacity ...
Type de document :
Article dans une revue scientifique: Article de synthèse/Review paper
DOI :
PMID :
URL permanente :
Titre :
Determining medical decision-making capacity in brain tumor patients: why and how?
Auteur(s) :
Pace, Andrea [Auteur]
Koekkoek, Johan A. F. [Auteur]
Leiden University Medical Center [LUMC]
Van Den Bent, Martin J. [Auteur]
Erasmus University Medical Center [Rotterdam] [Erasmus MC]
Bulbeck, Helen J. [Auteur]
Fleming, Jane [Auteur]
Grant, Robin [Auteur]
Golla, Heidrun [Auteur]
University Hospital of Cologne [Cologne]
Henriksson, Roger [Auteur]
Umeå University
Kerrigan, Simon [Auteur]
Marosi, Christine [Auteur]
Medizinische Universität Wien = Medical University of Vienna
Oberg, Ingela [Auteur]
Cambridge University Hospitals - NHS [CUH]
Oberndorfer, Stefan [Auteur]
St. Pölten University of Applied Sciences
Oliver, Kathy [Auteur]
Pasman, H. Roeline W. [Auteur]
Amsterdam University Medical Centers [Amsterdam UMC]
Le Rhun, Emilie [Auteur]
Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192
Rooney, Alasdair G. [Auteur]
University of Edinburgh [Edin.]
Ruda, Roberta [Auteur]
Università degli studi di Torino = University of Turin [UNITO]
Veronese, Simone [Auteur]
Walbert, Tobias [Auteur]
Henry Ford Health System
Weller, Michael [Auteur]
University hospital of Zurich [Zurich]
Wick, Wolfgang [Auteur]
Heidelberg University Hospital [Heidelberg]
Taphoorn, Martin J. B. [Auteur]
Leiden University Medical Center [LUMC]
Dirven, Linda [Auteur]
Leiden University Medical Center [LUMC]
Koekkoek, Johan A. F. [Auteur]
Leiden University Medical Center [LUMC]
Van Den Bent, Martin J. [Auteur]
Erasmus University Medical Center [Rotterdam] [Erasmus MC]
Bulbeck, Helen J. [Auteur]
Fleming, Jane [Auteur]
Grant, Robin [Auteur]
Golla, Heidrun [Auteur]
University Hospital of Cologne [Cologne]
Henriksson, Roger [Auteur]
Umeå University
Kerrigan, Simon [Auteur]
Marosi, Christine [Auteur]
Medizinische Universität Wien = Medical University of Vienna
Oberg, Ingela [Auteur]
Cambridge University Hospitals - NHS [CUH]
Oberndorfer, Stefan [Auteur]
St. Pölten University of Applied Sciences
Oliver, Kathy [Auteur]
Pasman, H. Roeline W. [Auteur]
Amsterdam University Medical Centers [Amsterdam UMC]
Le Rhun, Emilie [Auteur]
Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192
Rooney, Alasdair G. [Auteur]
University of Edinburgh [Edin.]
Ruda, Roberta [Auteur]
Università degli studi di Torino = University of Turin [UNITO]
Veronese, Simone [Auteur]
Walbert, Tobias [Auteur]
Henry Ford Health System
Weller, Michael [Auteur]
University hospital of Zurich [Zurich]
Wick, Wolfgang [Auteur]
Heidelberg University Hospital [Heidelberg]
Taphoorn, Martin J. B. [Auteur]
Leiden University Medical Center [LUMC]
Dirven, Linda [Auteur]
Leiden University Medical Center [LUMC]
Titre de la revue :
Neuro-oncology practice
Nom court de la revue :
Neurooncol Pract
Numéro :
7
Pagination :
599-612
Éditeur :
Oxford Academic
Date de publication :
2020-12-01
ISSN :
2054-2577
Mot(s)-clé(s) :
consent
glioma
brain metastases
neurodegenerative disease
capacity
glioma
brain metastases
neurodegenerative disease
capacity
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
BACKGROUND: Brain tumor patients are at high risk of impaired medical decision-making capacity (MDC), which can be ethically challenging because it limits their ability to give informed consent to medical treatments or ...
Lire la suite >BACKGROUND: Brain tumor patients are at high risk of impaired medical decision-making capacity (MDC), which can be ethically challenging because it limits their ability to give informed consent to medical treatments or participation in research. The European Association of Neuro-Oncology Palliative Care Multidisciplinary Task Force performed a systematic review to identify relevant evidence with respect to MDC that could be used to give recommendations on how to cope with reduced MDC in brain tumor patients. METHODS: A literature search in several electronic databases was conducted up to September 2019, including studies with brain tumor and other neurological patients. Information related to the following topics was extracted: tools to measure MDC, consent to treatment or research, predictive patient- and treatment-related factors, surrogate decision making, and interventions to improve MDC. RESULTS: A total of 138 articles were deemed eligible. Several structured capacity-assessment instruments are available to aid clinical decision making. These instruments revealed a high incidence of impaired MDC both in brain tumors and other neurological diseases for treatment- and research-related decisions. Incapacity appeared to be mostly determined by the level of cognitive impairment. Surrogate decision making should be considered in case a patient lacks capacity, ensuring that the patient's "best interests" and wishes are guaranteed. Several methods are available that may help to enhance patients' consent capacity. CONCLUSIONS: Clinical recommendations on how to detect and manage reduced MDC in brain tumor patients were formulated, reflecting among others the timing of MDC assessments, methods to enhance patients' consent capacity, and alternative procedures, including surrogate consent.Lire moins >
Lire la suite >BACKGROUND: Brain tumor patients are at high risk of impaired medical decision-making capacity (MDC), which can be ethically challenging because it limits their ability to give informed consent to medical treatments or participation in research. The European Association of Neuro-Oncology Palliative Care Multidisciplinary Task Force performed a systematic review to identify relevant evidence with respect to MDC that could be used to give recommendations on how to cope with reduced MDC in brain tumor patients. METHODS: A literature search in several electronic databases was conducted up to September 2019, including studies with brain tumor and other neurological patients. Information related to the following topics was extracted: tools to measure MDC, consent to treatment or research, predictive patient- and treatment-related factors, surrogate decision making, and interventions to improve MDC. RESULTS: A total of 138 articles were deemed eligible. Several structured capacity-assessment instruments are available to aid clinical decision making. These instruments revealed a high incidence of impaired MDC both in brain tumors and other neurological diseases for treatment- and research-related decisions. Incapacity appeared to be mostly determined by the level of cognitive impairment. Surrogate decision making should be considered in case a patient lacks capacity, ensuring that the patient's "best interests" and wishes are guaranteed. Several methods are available that may help to enhance patients' consent capacity. CONCLUSIONS: Clinical recommendations on how to detect and manage reduced MDC in brain tumor patients were formulated, reflecting among others the timing of MDC assessments, methods to enhance patients' consent capacity, and alternative procedures, including surrogate consent.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
INSERM
Université de Lille
Université de Lille
Collections :
Date de dépôt :
2022-06-15T13:59:54Z
2023-04-05T08:31:27Z
2023-04-05T08:31:27Z
Fichiers
- 2020-12-01-npaa040.pdf
- Version éditeur
- Accès libre
- Accéder au document